research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
Search
for
Sort by
Research
270-300 / 1000+ resultsresearch Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
research Glycogen Phosphorylase Inhibitor Promotes Hair Growth via Protecting from Oxidative-Stress and Regulating Glycogen Breakdown in Human Hair follicles
A new compound, HTPI, promotes hair growth by protecting cells from damage and regulating energy use.
research Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
research Integrin-linked kinase inhibition via QLT0267 stops the epithelial outgrowth.
QLT0267 stops hair follicle cell growth and movement.
research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
research Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Glucocorticoid Receptor Antagonism Improves Glucose Metabolism in a Mouse Model of Polycystic Ovary Syndrome
Blocking glucocorticoid receptors improves glucose metabolism in a PCOS mouse model.
research Alopecia Universalis: Never Give Up?
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Baricitinib as a treatment for myasthenia gravis: A case report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab
Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
research DRUG NEWS
The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
research The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation
Gefitinib can cause hair and eyebrow darkening.
research Simultaneous effects of tocopheryl polyethylene glycol succinate (TPGS) on local hair growth promotion and systemic absorption of topically applied minoxidil in a mouse model
Adding a small amount of TPGS to minoxidil can help hair growth, but too much TPGS reduces this effect and increases minoxidil in the blood.
research Modulation of glucocorticoid action and the treatment of type-2 diabetes
Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.
research Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide
Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo
TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
research Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma
Adverse events from vismodegib can be managed effectively to ensure optimal treatment.
research Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature
An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
research Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.